PCMdt-MMAE with a TSC of 0.35 mg/kg reduced the tumor volume by up to 93%, decreased the tumor weight by up to 96%, and eradicated tumors by up to 20% in HT29 tumors expressing high levels of MET and RON (Fig. 5a and Table 2A). This evidence concerns the gene MET and neoplasm.